NCT00927901View on ClinicalTrials.gov

Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Salts in Patients With Asthma

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions
Asthma
Interventions
DRUG

Indacaterol maleate 400 μg

Indacaterol maleate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.

DRUG

Indacaterol acetate 400 μg

Indacaterol acetate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.

DRUG

Indacaterol xinafoate 400 μg

Indacaterol xinafoate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.

DRUG

Placebo to indacaterol

Placebo to indacaterol was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler.

Trial Locations (3)

Unknown

Novartis Investigative Site, Poitiers

Novartis Investigative Site, Wiesbaden

Novartis Investigative Site, Verona

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY